<DOC>
	<DOCNO>NCT01012011</DOCNO>
	<brief_summary>This surveillance identify problems/questions regard adverse event , factor consider affect safety efficacy clinical practice use Nexavar</brief_summary>
	<brief_title>Regulatory Post Marketing Surveillance Study Nexavar®</brief_title>
	<detailed_description>The objective surveillance identify problems/questions regard following clinical practice use Nexavar® . 1 . Unknown adverse event ( particular , serious adverse event ) 2 . Identification adverse event occur real practice . 3 . Factors consider affect safety . 4 . Factors consider affect effectiveness</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Patients diagnosis advance RCC HCC decision take physician prescribe Nexavar . Exclusion criterion must read conjunction local product information patient participate interventional study currently exclude .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>91 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Carcinoma , Hepatocellular</keyword>
	<keyword>Carcinoma , Renal Cell</keyword>
</DOC>